Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trials
- Design
- Meta-analysis · Intermediate outcome
- Match to healthy normal-weight adults aged 55–75
- Partial matchPD patients not selected for weight or diabetes; disease-specific outcomes.
- Could weight loss explain it?
- Unlikely[Auto] Not addressed in abstract.
- Study tier
- Study tier 2Meta-analysis of RCTs concluding no consistent benefit.
- Assessment
- Version 4 · Checked against the source by AI · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
A 2026 meta-analysis of randomized trials found no statistically significant benefit of GLP-1 drugs on motor or non-motor Parkinson's outcomes, except a small improvement in quality of life (PDQ-39 MD -0.75), and more gastrointestinal side effects. The authors say current evidence does not show consistent clinical benefit or support these drugs as disease-modifying therapy.
01Findings
What the study reported
- Drugs
- Exenatide, Lixisenatide, Liraglutide, Class unspecified
- Comparator
- placebo
- Primary outcome
- MDS-UPDRS III (on and off) in RCTs of GLP-1RAs in Parkinson's disease
- Effect
- No significant benefit on motor or non-motor outcomes; PDQ-39 MD -0.75 (small); more GI adverse events
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Not extracted
Who was studied
- Obesity status
- not selected for weight
- Baseline condition
- Parkinson's disease
Study quality details
- Study design
- Meta-analysis
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- not stated
- Comparator
- placebo
- Follow up duration
- not stated
- Outcome type
- mixed
- Replication
- pooled RCTs including the phase 3 exenatide trial
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- PARTIAL
- Statistical precision
- CI reported: 95% CI: [- 1
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- Not stated
- Industry funded
- No
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- Authors declare no conflicts.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
03Claims
Claims this study bears on
- GLP-1 receptor agonists slow progression of Parkinson's disease.Contradicts
Meta-analysis of RCTs in Parkinson's disease: no significant benefit on motor or non-motor outcomes except a small PDQ-39 improvement (MD -0.75; 95% CI -1.34 to -0.17); more adverse events, mainly gastrointestinal.
04Source
The source, as retrieved
Abstract
[BACKGROUND] Parkinson's disease (PD) is a progressive neurodegenerative disorder with no proven disease-modifying therapies to date. Because changes in cerebral glucose metabolism and insulin resistance have been linked to PD pathophysiology, glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for diabetes, have been investigated as potential neuroprotective treatments. [METHODS] This study systematically assessed the efficacy and safety of GLP-1RAs in PD through a systematic review and meta-analysis of randomized controlled trials identified in PubMed, Embase, and the Cochrane Library. The primary outcomes were motor function improvements measured by the MDS-UPDRS Part III in both on- and off-medication states at study endpoints and at intermediate timepoints of interest. Secondary outcomes included MDS-UPDRS Parts I, II, and IV, quality of life assessed by the PDQ-39, levodopa equivalent daily dose (LEDD), and the occurrence of adverse events. [RESULTS] The meta-analysis found no statistically significant difference in favor of GLP-1RAs over placebo for motors and non-motors outcomes, except for PDQ-39 (MD: - 0.75; 95% CI: [- 1.34, - 0.17], P = 0.01). Regarding safety, GLP-1RAs were associated with a higher incidence of adverse events, especially gastrointestinal effects such as nausea, vomiting, and constipation. [CONCLUSIONS] Overall, current evidence does not demonstrate consistent clinical benefit of using GLP-1RAs for treating motor or non-motor symptoms in PD nor support GLP-1RAs as disease-modifying therapy, underscoring the need for further research.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 42105060 first ingestion |